TW202233666A - 減少人類對象中之ｔａｕ的方法 - Google Patents

減少人類對象中之ｔａｕ的方法 Download PDF

Info

Publication number
TW202233666A
TW202233666A TW110139444A TW110139444A TW202233666A TW 202233666 A TW202233666 A TW 202233666A TW 110139444 A TW110139444 A TW 110139444A TW 110139444 A TW110139444 A TW 110139444A TW 202233666 A TW202233666 A TW 202233666A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
chain variable
days
Prior art date
Application number
TW110139444A
Other languages
English (en)
Chinese (zh)
Inventor
溫迪 加爾彭
馬丁 提姆斯
湯姆 雅各布斯
帕沙 南迪
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202233666A publication Critical patent/TW202233666A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110139444A 2020-10-26 2021-10-25 減少人類對象中之ｔａｕ的方法 TW202233666A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26

Publications (1)

Publication Number Publication Date
TW202233666A true TW202233666A (zh) 2022-09-01

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110139444A TW202233666A (zh) 2020-10-26 2021-10-25 減少人類對象中之ｔａｕ的方法

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Also Published As

Publication number Publication date
MX2023004831A (es) 2023-07-12
US20220127345A1 (en) 2022-04-28
KR20230093499A (ko) 2023-06-27
IL302386A (en) 2023-06-01
CA3199806A1 (en) 2022-05-05
AU2021367878A1 (en) 2023-06-22
JP2023546504A (ja) 2023-11-02
EP4232155A1 (en) 2023-08-30
WO2022090158A1 (en) 2022-05-05
CN116916955A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
JP7241058B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
CN106390107B (zh) 病理tau蛋白的免疫靶向
TWI705824B (zh) 治療阿茲海默症之方法
US20230123110A1 (en) High dose treatments for alzheimer's disease
TW202233666A (zh) 減少人類對象中之ｔａｕ的方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (zh) 减少人类受试者中的tau的方法
JP2024509956A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116829582A (zh) 安全施用抗Tau抗体的方法
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
HK40100358A (zh) 安全施用抗tau抗体的方法
HK1261507A1 (en) High dose treatments for alzheimer's disease